Consultants in Pain Management, PC
Consultants in Pain Management, PC was paid $1000K by Medicaid between Jan 2018 and Dec 2024, across 58 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 77% of everything it billed.
33Billing provider infoCONSULTANTS IN PAIN MANAGEMENT, PC
CHATTANOOGA, TN 37421
CHATTANOOGA, TN 37421
33aNPI1275607129assigned 11/20/2006
33bProvider typeRegistered Nurse
28Total paid$1000K
24GClaims91,473
24DCodes billed58
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Registered Nurse providers in Tennessee
Rank by total paid#3 of 79
Median peer was paid$5K
This provider vs. median200×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 18,838 | $205K | |
| 2019 | 14,037 | $193K | |
| 2020 | 13,213 | $149K | |
| 2021 | 12,291 | $128K | |
| 2022 | 10,918 | $118K | |
| 2023 | 13,831 | $125K | |
| 2024incomplete | 8,345 | $81K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 77% | 48,058 | 33,788 | $765K |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | 9.4% | 2,927 | 2,128 | $94K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 7.4% | 13,319 | 8,295 | $74K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 1.3% | 1,129 | 768 | $13K |
| 80305 | <1% | 824 | 736 | $8K | |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | <1% | 1,719 | 1,019 | $6K |
| 99204 | Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | <1% | 111 | 54 | $5K |
| 96127 | <1% | 2,935 | 2,083 | $3K | |
| 90791 | Psychiatric diagnostic evaluationPsychiatric diagnostic evaluation | <1% | 125 | 91 | $3K |
| 99443 | <1% | 154 | 115 | $3K | |
| 27096 | <1% | 34 | 24 | $2K | |
| 83970 | <1% | 367 | 232 | $2K |
46 more codes
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 602 | $2K |
| 80053 | Comprehensive metabolic panel | <1% | 1,547 | $2K |
| 81025 | <1% | 521 | $1K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 310 | $1K |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | <1% | 171 | $1K |
| 82627 | <1% | 406 | $1K | |
| 84270 | <1% | 410 | $1K | |
| 84481 | <1% | 415 | $965.82 | |
| 36415 | Collection of venous blood by venipuncture | <1% | 1,777 | $853.77 |
| 82746 | <1% | 449 | $847.94 | |
| 82607 | <1% | 405 | $800.23 | |
| 86141 | <1% | 445 | $727.01 | |
| 83003 | <1% | 283 | $655.26 | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 15 | $631.67 |
| 83735 | <1% | 416 | $577.36 | |
| 83690 | <1% | 405 | $563.42 | |
| 82728 | <1% | 412 | $560.89 | |
| 82150 | <1% | 454 | $558.48 | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 77 | $551.98 |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 471 | $541.61 |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 310 | $498.80 |
| 84439 | <1% | 393 | $454.98 | |
| 84146 | <1% | 113 | $395.23 | |
| 83090 | <1% | 102 | $361.57 | |
| 83615 | <1% | 402 | $348.07 | |
| 83550 | <1% | 354 | $338.20 | |
| 86431 | <1% | 395 | $306.30 | |
| 85652 | <1% | 406 | $280.55 | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 314 | $265.73 |
| 83540 | <1% | 392 | $262.86 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 284 | $110.61 |
| 84100 | <1% | 17 | $6.35 | |
| 1036F | 0% | 550 | $0.00 | |
| 4000F | 0% | 23 | $0.00 | |
| G8510 | Screening for depression is documented as negative, a follow-up plan is not required | 0% | 223 | $0.00 |
| G8730 | Pain assessment documented as positive using a standardized tool and a follow-up plan is documented | 0% | 2,799 | $0.00 |
| 4004F | 0% | 86 | $0.00 | |
| 99072 | 0% | 1,563 | $0.00 | |
| 3288F | 0% | 29 | $0.00 | |
| G8431 | Screening for depression is documented as being positive and a follow-up plan is documented | 0% | 534 | $0.00 |
| G2211 | Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) | 0% | 385 | $0.00 |
| G8918 | Patient without preoperative order for iv antibiotic surgical site infection (ssi) prophylaxis | 0% | 12 | $0.00 |
| G8427 | Eligible clinician attests to documenting in the medical record they obtained, updated, or reviewed the patient's current medications | 0% | 40 | $0.00 |
| G8907 | Patient documented not to have experienced any of the following events: a burn prior to discharge; a fall within the facility; wrong site/side/patient/procedure/implant event; or a hospital transfer or hospital admission upon discharge from the facility | 0% | 19 | $0.00 |
| G8417 | Bmi is documented above normal parameters and a follow-up plan is documented | 0% | 21 | $0.00 |
| G8783 | Normal blood pressure reading documented, follow-up not required | 0% | 14 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialBAYSORE, ANDREW (PRACTICE ADMINISTRATOR)